lmmunofluorescence Studies. First passage HUVEC were grown to confluence in microtiter wells in medium 199 containing 20% FCS. The wells were gently washed several times with serum-free medium. The cell monolayers were incubated for 1 h at 37°C with either a mixture of anti-DAF mAb or normal mouse IgG at a final concentration of 10 tzg/ml each in PBS, washed three times with PBS, and then incubated with fluoresceinated goat anti-mouse IgG antibody (Cappel Laboratories, Cochranville, PA). The monolayers were again washed three times with PBS and examined with a Leitz fluorescence microscope.
FACS Analysis. ~ 107 first passage H UVEC obtained by scraping the bottom of culture flasks with a rubber policeman were resuspended in PBS, pH 7.4 containing 1% BSA, 0.1% sodium azide, and 5 mM EDTA. After washing, the cells were divided into aliquots and incubated with a mixture of mAb against DAF (5 12g/ml each) for 30 min on ice. The cells were washed three times with the same PBS and incubated with a fluoresceinated goat F(ab')~ anti-mouse IgG (H and L chain-specific) (Cappel Laboratories) for 30 rain on ice. After washing three times with the same PBS, the cells were analyzed by flow cytometry. Controls included normal peripheral blood cells stained with the mixture of anti-DAF mAb, as well as cells incubated with irrelevant mAb of the same subclasses as the primary antibody.
Two-site Immunoradiometric Analysis of Endothelial Cells.
This was performed as described previously (8) . In brief, anti-DAF monoclonal IA10 was used as a capturing antibody to coat wells of plastic plates. Cell extracts or serial dilutions of pure DAF were added to the wells. After incubation and washing, bound DAF was detected by ~25I-labeled anti-DAF monoclonal IIH6, which recognizes a different epitope from IA 10. The amounts of DAF in the cell extracts were calculated from a standard curve obtained with purified DAF. This standard curve, in which counts bound of the revealing antibody were plotted as a function of DAF concentration, was linear up to 250 ng DAF/ml. The protein concentration was measured by the method of Lowry et al. (17) using BSA as a reference protein.
Western Blotting of Endothelial Cell Extract. Protein A-Sepharose (100 121) was incubated with 5 ml of culture supernatant containing mAb IA10 for 1 h at room temperature. IA10-protein A-Sepharose was washed twice with PBS and then incubated with NP-40 extracts of H UVEC (20 t21 beads per 1 ml of the extract) for 1 h at 4 oc. The bound DAF molecules were eluted from the beads by incubation for 5 rain at 80°C with 50 121 of sample buffer consisting of 5% SDS/125 mM Tris HCI, pH 6.8/10% glycerol/0.01% bromphenol blue. The eluates were subjected to SDS-PAGE (16) using 7.5% gels and transferred electrophoretically to nitrocellulose paper (18) (19) (20) . DAF was detected on the nitrocellulose paper using ~25I-labeled IA10 followed by autoradiography.
Biosynthetic Labeling of DAF with [sSS]Methionine. [35S]methionine-labeled DAF was
isolated from HUVEC radiolabeled with [3~S]methionine (100 12Ci/mi for 20 h) with a mixture of anti-DAF mAb, as described previously for the isolation of thrombospondin from HUVEC (16) . The immunoisolated proteins were analyzed by SDS-PAGE with a 4% stacking gel and 7.5% separation gel (19) , followed by autoradiography of the gel after treatment with an autoradiography enhancer (ENnHANCE; New England Nuclear, Boston, MA). Molecular weights were estimated using ~4C-labeled marker proteins (New England Nuclear): phosphorylase (94,000), BSA (67,000), arid ovalbumin (45,000).
Results and Discussion
The initial studies to determine whether DAF was present on the surface of endothelial cells were performed using indirect immunofluorescence and light microscopy. Live confluent monolayers of HUVEC were incubated with a mixture of all three anti-DAF mAb, washed, and incubated with fluoresceinated goat anti-mouse IgG. Surface fluorescence was visible on all cells in the monolayer. Control studies using normal mouse IgG as a primary antibody followed by the fluorescent second antibody were negative (data not shown). When analyzed by flow cytometry (FACS), the endothelial cells displayed surface fluorescence intensity that was approximately four times that of peripheral blood monocytes and seven times that of neutrophils (Fig. 1) . Control FACS studies on endothelial cells stained with irrelevant monoclonals of the same subclasses were negative.
To quantitate the number of DAF molecules per cell, a known number of endothelial cells were solubilized with NP-40 and the amount of DAF in the extract determined by double antibody RIA. An average of 3.3 × 10 ~ molecules of DAF were present on each endothelial cell, a much higher value than that obtained for blood cells (11) .
By Western blotting, endothelial cell DAF comigrated with purified erythrocyte DAF (Fig. 2) . Western blots of the same samples performed with an irrelevant monoclonal of the same subclasses were negative (data not shown). To demonstrate that the DAF present in endothelial cells was synthesized by the cells, nearly confluent HUVEC were labeled for 20 h with [3~S]methionine and solubilized, and ~SS-labeled DAF was immunoisolated using a mixture of anti-DAF mAb. SDS-PAGE and autoradiography of the immunoisolate demonstrated the presence of immunoreactive DAF of mol wt 70,000 synthesized by cultured human endothelial cells (Fig. 3) , showing de nova synthesis of DAF. Normal mouse IgG failed to immunoprecipitate any radioactivity.
Like peripheral blood cells, endothelial cells are continuously exposed to the plasma milieu and are susceptible to complement-mediated cell damage. Our own data demonstrates the presence and synthesis of DAF by HUVEC. This is the first evidence for the presence of DAF in cells of extra-marrow origin. DAF may have a role in protecting the endothelial cell from complement-mediated damage. Deficiency or disorders of DAF function may result in endothelial cell injury and may thus play an important role in a variety of pathologic conditions. Exposed subendothelium may lead to platelet deposition with subsequent degranulation and release of thrombogenic materials. In addition, platelet-derived growth factor released under these circumstances may lead to smooth muscle cell proliferation. Alternatively, under some conditions, the accelerated deposition of activated complement products on the endothelial cell surface may result in the recruitment of inflammatory cells and vasculitis. 
Summary
Decay-accelerating factor (DAF) has been previously described only in cells of bone marrow origin where it serves as a negative modulator of complement activation. Using mAb against human DAF, we demonstrated the presence of DAF in human umbilical vein endothelial cells by immunofluorescence microscopy and flow cytometry. By means of an immunoradiometric assay we detected an average of 3.3 × l0 p molecules of DAF on each cell. When immunoisolates were analyzed in Western blots, endothelial cell DAF comigrated with DAF purified from normal erythrocytes. DAF was synthesized by the endothelial cells since SsS-labeled DAF could be immunoisolated from HUVEC cultured in medium containing [S~S] methionine. This is the first evidence for the presence of DAF in cells of extra-marrow origin. DAF may protect endothelial cells from complement-mediated injury.
